Sarbajit Mukherjee, Chief of GI Medical Oncology at Miami Cancer Institute and Co-Chair of GI Clinical Trial Working Group at Hoosier Cancer Research Network, shared a post on LinkedIn:
“The new ASCO Guideline Update on immunotherapy and targeted therapy for advanced gastroesophageal cancer is now published in Journal of Clinical Oncology
The emphasis is on biomarker testing and biomarker-driven treatment.
Key highlights:
- Upfront testing for HER2, PD-L1, MSI/MMR, and CLDN18.2 is essential
- PD-L1 ≥1: Immunotherapy + platinum/fluoropyrimidine chemotherapy (with greater benefit as PD-L1 increases, especially ≥10)
- CLDN18.2-positive disease: Zolbetuximab + chemotherapy is now a standard option
- HER2-positive, PD-L1 ≥1: Pembrolizumab + trastuzumab + chemotherapy
- dMMR/MSI-H: Immunotherapy-based strategies remain foundational
Grateful to American Society of Clinical Oncology (ASCO) and Manish Shah for the opportunity to contribute alongside an exceptional panel.
And this is just the beginning – antibody–drug conjugates and bispecific antibodies are poised to further reshape the treatment landscape in the years ahead.”
Title: Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update
Authors: Manish A. Shah, Erin B. Kennedy, Dana Deighton, Minaxi Jhawer, Kunal C. Kadakia, Sarbajit Mukherjee, Christopher Nevala-Plagemann, Anwaar Saeed, Bryan J. Schneider, Thomas Semrad, Kohei Shitara, Laura Tenner, Nataliya V. Uboha, Melani Vincelli, Davit Zohrabyan, Lakshmi Rajdev
Read the Full Article.
Other articles featuring Sarbajit Mukherjee on OncoDaily.